Tumor Necrosis Factor Alpha Inhibitors and Cardiovascular Risk in Rheumatoid Arthritis.
Biologics
Cardiovascular risk
Chronic heart failure
Rheumatoid arthritis
Tumor necrosis factor
Journal
Clinical reviews in allergy & immunology
ISSN: 1559-0267
Titre abrégé: Clin Rev Allergy Immunol
Pays: United States
ID NLM: 9504368
Informations de publication
Date de publication:
29 Dec 2023
29 Dec 2023
Historique:
accepted:
01
12
2023
medline:
2
1
2024
pubmed:
2
1
2024
entrez:
29
12
2023
Statut:
aheadofprint
Résumé
Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by an increased risk of cardiovascular events, due to the complex interplay between traditional and disease-related risk factors. Chronic inflammation and persistent disease activity are the key determinants of this risk, but despite great improvement in the disease management and prognosis, cardiovascular events are still the main cause of morbidity and mortality in RA cohorts
Identifiants
pubmed: 38157095
doi: 10.1007/s12016-023-08975-z
pii: 10.1007/s12016-023-08975-z
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Løgstrup BB, Ellingsen T, Pedersen AB et al (2021) Cardiovascular risk and mortality in rheumatoid arthritis compared with diabetes mellitus and the general population. Rheumatology 60(3):1400–1409. https://doi.org/10.1093/RHEUMATOLOGY/KEAA374
doi: 10.1093/RHEUMATOLOGY/KEAA374
pubmed: 32984893
van der Woude D, van der Helm-van Mil AHM (2018) Update on the epidemiology, risk factors, and disease outcomes of rheumatoid arthritis. Best Pract Res Clin Rheumatol 32(2):174–187. https://doi.org/10.1016/J.BERH.2018.10.005
doi: 10.1016/J.BERH.2018.10.005
pubmed: 30527425
Conforti A, Di Cola I, Pavlych V et al (2021) Beyond the joints, the extra-articular manifestations in rheumatoid arthritis. Autoimmun Rev 20(2):102735. https://doi.org/10.1016/J.AUTREV.2020.102735
doi: 10.1016/J.AUTREV.2020.102735
pubmed: 33346115
Liao KP (2017) Cardiovascular disease in patients with rheumatoid arthritis. Trends Cardiovasc Med 27(2):136–140. https://doi.org/10.1016/J.TCM.2016.07.006
doi: 10.1016/J.TCM.2016.07.006
pubmed: 27612551
Maradit-Kremers H, Crowson CS, Nicola PJ et al (2005) Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 52(2):402–411. https://doi.org/10.1002/ART.20853
doi: 10.1002/ART.20853
pubmed: 15693010
Nicola PJ, Crowson CS, Maradit-Kremers H et al (2006) Contribution of congestive heart failure and ischemic heart disease to excess mortality in rheumatoid arthritis. Arthritis Rheum 54(1):60–67. https://doi.org/10.1002/ART.21560
doi: 10.1002/ART.21560
pubmed: 16385496
Gabriel SE (2008) Cardiovascular morbidity and mortality in rheumatoid arthritis. Am J Med 121(10 SUPPL 1). https://doi.org/10.1016/J.AMJMED.2008.06.011
Rheumatology A, Center I, Hansildaar R et al (2021) Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout. Lancet Rheumatol 3(1):e58-e70. https://doi.org/10.1016/S2665-9913(20)30221-6
Aviña-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D (2008) Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Care Res (Hoboken) 59(12):1690–1697. https://doi.org/10.1002/ART.24092
doi: 10.1002/ART.24092
Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D (2012) Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 71(9):1524–1529. https://doi.org/10.1136/ANNRHEUMDIS-2011-200726
doi: 10.1136/ANNRHEUMDIS-2011-200726
pubmed: 22425941
Boyer JF, Gourraud PA, Cantagrel A, Davignon JL, Constantin A (2011) Traditional cardiovascular risk factors in rheumatoid arthritis: a meta-analysis. Joint Bone Spine 78(2):179–183. https://doi.org/10.1016/J.JBSPIN.2010.07.016
doi: 10.1016/J.JBSPIN.2010.07.016
pubmed: 20851020
Skeoch S, Bruce IN (2015) Atherosclerosis in rheumatoid arthritis: is it all about inflammation? Nature Rev Rheumatol 11(7):390–400. https://doi.org/10.1038/nrrheum.2015.40
Libby P (2012) Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 32(9):2045–2051. https://doi.org/10.1161/ATVBAHA.108.179705
doi: 10.1161/ATVBAHA.108.179705
pubmed: 22895665
pmcid: 3422754
Chia S, Qadan M, Newton R, Ludlam CA, Fox KAA, Newby DE (2003) Intra-arterial tumor necrosis factor-alpha impairs endothelium-dependent vasodilatation and stimulates local tissue plasminogen activator release in humans. Arterioscler Thromb Vasc Biol 23(4):695–701. https://doi.org/10.1161/01.ATV.0000065195.22904.FA
doi: 10.1161/01.ATV.0000065195.22904.FA
pubmed: 12692009
Legein B, Temmerman L, Biessen EAL, Lutgens E (2013) Inflammation and immune system interactions in atherosclerosis. Cell Mol Life Sci 70(20):3847–3869. https://doi.org/10.1007/S00018-013-1289-1
doi: 10.1007/S00018-013-1289-1
pubmed: 23430000
Hossain MB, Kopec JA, Atiquzzaman M, Karim ME (2022) The association between rheumatoid arthritis and cardiovascular disease among adults in the United States during 1999–2018, and age-related effect modification in relative and absolute scales. Ann Epidemiol 71:23–30. https://doi.org/10.1016/j.annepidem.2022.03.005
doi: 10.1016/j.annepidem.2022.03.005
pubmed: 35301105
Fraenkel L, Bathon JM, England BR et al (2021) 2021 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 73(7):924–939. https://doi.org/10.1002/ACR.24596
doi: 10.1002/ACR.24596
pubmed: 34101387
Ytterberg SR, Bhatt DL, Mikuls TR et al (2022) Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 386(4):316–326. https://doi.org/10.1056/NEJMOA2109927/SUPPL_FILE/NEJMOA2109927_DATA-SHARING.PDF
doi: 10.1056/NEJMOA2109927/SUPPL_FILE/NEJMOA2109927_DATA-SHARING.PDF
pubmed: 35081280
Nurmohamed MT (2009) Cardiovascular risk in rheumatoid arthritis. Autoimmun Rev 8(8):663–667. https://doi.org/10.1016/j.autrev.2009.02.015
doi: 10.1016/j.autrev.2009.02.015
pubmed: 19393192
Fakih O, Desmarets M, Martin B et al (2023) Impact of NSAIDs on 8-year cumulative incidence of major cardiovascular events in patients with ankylosing spondylitis: a nationwide study. Rheumatology (Oxford). Published online. https://doi.org/10.1093/RHEUMATOLOGY/KEAD072
Roubille C, Richer V, Starnino T et al (2015) The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 74(3):480–489. https://doi.org/10.1136/ANNRHEUMDIS-2014-206624
doi: 10.1136/ANNRHEUMDIS-2014-206624
pubmed: 25561362
Eder L, Thavaneswaran A, Chandran V, Cook R, Gladman DD (2015) Increased burden of inflammation over time is associated with the extent of atherosclerotic plaques in patients with psoriatic arthritis. Ann Rheum Dis 74(10):1830–1835. https://doi.org/10.1136/ANNRHEUMDIS-2014-205267
doi: 10.1136/ANNRHEUMDIS-2014-205267
pubmed: 24827532
Heslinga M, Van Den Oever IAM, Jonker DL et al (2019) Suboptimal cardiovascular risk management in rheumatoid arthritis patients despite an explicit cardiovascular risk screening programme. Scand J Rheumatol 48(5):345–352. https://doi.org/10.1080/03009742.2019.1600718
doi: 10.1080/03009742.2019.1600718
pubmed: 31210083
Van Den Oever IAM, Heslinga M, Griep EN et al Cardiovascular risk management in rheumatoid arthritis patients still suboptimal: the Implementation of Cardiovascular Risk Management in Rheumatoid Arthritis project. https://doi.org/10.1093/rheumatology/kew497
U-prevent. Accessed November 2, 2023. https://u-prevent.nl/accept-terms
Raadsen R, Agca R, Boers M et al (2023) In RA patients without prevalent CVD, incident CVD is mainly associated with traditional risk factors: a 20-year follow-up in the CARRÉCARR´CARRÉ cohort study. Semin Arthritis Rheum 58:152132. https://doi.org/10.1016/j.semarthrit.2022.152132
doi: 10.1016/j.semarthrit.2022.152132
pubmed: 36434892
Chang K, Yang SM, Kim SH, Han KH, Park SJ, Shin J (2014) Il. Smoking and rheumatoid arthritis. Int J Mol Sci 15(12):22279–22295. https://doi.org/10.3390/IJMS151222279
Saevarsdottir S, Rezaei H, Geborek P et al (2015) Current smoking status is a strong predictor of radiographic progression in early rheumatoid arthritis: results from the SWEFOT trial. Ann Rheum Dis 74(8):1509–1514. https://doi.org/10.1136/ANNRHEUMDIS-2013-204601
doi: 10.1136/ANNRHEUMDIS-2013-204601
pubmed: 24706006
Siasos G, Tsigkou V, Kokkou E et al (2014) Smoking and atherosclerosis: mechanisms of disease and new therapeutic approaches. Curr Med Chem 21(34):3936–3948. https://doi.org/10.2174/092986732134141015161539
doi: 10.2174/092986732134141015161539
pubmed: 25174928
Derksen VFAM, Huizinga TWJ, van der Woude D (2017) The role of autoantibodies in the pathophysiology of rheumatoid arthritis. Semin Immunopathol 39(4):437–446. https://doi.org/10.1007/S00281-017-0627-Z
doi: 10.1007/S00281-017-0627-Z
pubmed: 28451788
pmcid: 5486798
Hyrich KL, Watson KD, Silman AJ, Symmons DPM (2006) Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 45(12):1558–1565. https://doi.org/10.1093/RHEUMATOLOGY/KEL149
doi: 10.1093/RHEUMATOLOGY/KEL149
pubmed: 16705046
Law-Wan J, Sparfel MA, Derolez S et al (2021) Predictors of response to TNF inhibitors in rheumatoid arthritis: an individual patient data pooled analysis of randomised controlled trials. Open 7:1882. https://doi.org/10.1136/rmdopen-2021-001882
doi: 10.1136/rmdopen-2021-001882
Messner B, Bernhard D (2014) Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis. Arterioscler Thromb Vasc Biol 34(3):509–515. https://doi.org/10.1161/ATVBAHA.113.300156
doi: 10.1161/ATVBAHA.113.300156
pubmed: 24554606
Roelsgaard IK, Ikdahl E, Rollefstad S et al (2020) Smoking cessation is associated with lower disease activity and predicts cardiovascular risk reduction in rheumatoid arthritis patients. Rheumatology (Oxford) 59(8):1997–2004. https://doi.org/10.1093/RHEUMATOLOGY/KEZ557
doi: 10.1093/RHEUMATOLOGY/KEZ557
pubmed: 31782789
Santo RCE, Fernandes KZ, Lora PS, Filippin LI, Xavier RM (2018) Prevalence of rheumatoid cachexia in rheumatoid arthritis: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle 9(5):816–825. https://doi.org/10.1002/JCSM.12320
doi: 10.1002/JCSM.12320
pubmed: 30133186
pmcid: 6204596
Giles JT, Allison M, Blumenthal RS et al (2010) Abdominal adiposity in rheumatoid arthritis: association with cardiometabolic risk factors and disease characteristics. Arthritis Rheum 62(11):3173–3182. https://doi.org/10.1002/ART.27629
doi: 10.1002/ART.27629
pubmed: 20589684
pmcid: 2962724
Kremers HM, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE (2004) Prognostic importance of low body mass index in relation to cardiovascular mortality in rheumatoid arthritis. Arthritis Rheum 50(11):3450–3457. https://doi.org/10.1002/ART.20612
doi: 10.1002/ART.20612
pubmed: 15529378
Summers GD, Metsios GS, Stavropoulos-Kalinoglou A, Kitas GD (2010) Rheumatoid cachexia and cardiovascular disease. Nat Rev Rheumatol 6(8):445–451. https://doi.org/10.1038/NRRHEUM.2010.105
doi: 10.1038/NRRHEUM.2010.105
pubmed: 20647995
Lupoli R, Pizzicato P, Scalera A et al (2016) Impact of body weight on the achievement of minimal disease activity in patients with rheumatic diseases: a systematic review and meta-analysis. Arthritis Res Ther 18(1). https://doi.org/10.1186/S13075-016-1194-8
Klaasen R, Wijbrandts CA, Gerlag DM, Tak PP (2011) Body mass index and clinical response to infliximab in rheumatoid arthritis. Arthritis Rheum 63(2):359–364. https://doi.org/10.1002/ART.30136
Ellulu MS, Patimah I, Khaza’ai H, Rahmat A, Abed Y (2017) Obesity and inflammation: the linking mechanism and the complications. Arch Med Sci 13(4):851–863. https://doi.org/10.5114/AOMS.2016.58928
Hahn BH, Grossman J, Chen W, McMahon M (2007) The pathogenesis of atherosclerosis in autoimmune rheumatic diseases: roles of inflammation and dyslipidemia. J Autoimmun 28(2–3):69–75. https://doi.org/10.1016/J.JAUT.2007.02.004
doi: 10.1016/J.JAUT.2007.02.004
pubmed: 17433865
Robertson J, Peters MJ, McInnes IB, Sattar N (2013) Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm. Nat Rev Rheumatol 9(9):513–523. https://doi.org/10.1038/NRRHEUM.2013.91
doi: 10.1038/NRRHEUM.2013.91
pubmed: 23774906
Berbée JFP, Havekes LM, Rensen PCN (2005) Apolipoproteins modulate the inflammatory response to lipopolysaccharide. J Endotoxin Res 11(2):97–103. https://doi.org/10.1179/096805105X35215
doi: 10.1179/096805105X35215
pubmed: 15949136
Netea MG, Demacker PNM, Kullberg BJ et al (1996) Low-density lipoprotein receptor-deficient mice are protected against lethal endotoxemia and severe gram-negative infections. J Clin Invest 97(6):1366–1372. https://doi.org/10.1172/JCI118556
doi: 10.1172/JCI118556
pubmed: 8617867
pmcid: 507194
Popa C, Netea MG, De Graaf J et al (2009) Circulating leptin and adiponectin concentrations during tumor necrosis factor blockade in patients with active rheumatoid arthritis. J Rheumatol 36(4):724–730. https://doi.org/10.3899/JRHEUM.080626
doi: 10.3899/JRHEUM.080626
pubmed: 19273452
Myasoedova E, Crowson CS, Kremers HM et al (2011) Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 70(3):482–487. https://doi.org/10.1136/ARD.2010.135871
doi: 10.1136/ARD.2010.135871
pubmed: 21216812
Memon RA, Grunfeld C, Moser AH, Feingold KR (1993) Tumor necrosis factor mediates the effects of endotoxin on cholesterol and triglyceride metabolism in mice. Endocrinology 132(5):2246–2253. https://doi.org/10.1210/ENDO.132.5.8477669
doi: 10.1210/ENDO.132.5.8477669
pubmed: 8477669
Schreyer SA, Peschon JJ, LeBoeuf RC (1996) Accelerated atherosclerosis in mice lacking tumor necrosis factor receptor p55. J Biol Chem 271(42):26174–26178. https://doi.org/10.1074/JBC.271.42.26174
doi: 10.1074/JBC.271.42.26174
pubmed: 8824264
Popa C, Netea MG, Van Riel PLCM, Van Der Meer JWM, Stalenhoef AFH (2007) The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res 48(4):751–752. https://doi.org/10.1194/JLR.R600021-JLR200
doi: 10.1194/JLR.R600021-JLR200
pubmed: 17202130
Ettinger WH, Varma VK, Sorci-Thomas M et al (1994) Cytokines decrease apolipoprotein accumulation in medium from Hep G2 cells. Arterioscler Thromb 14(1):8–13. https://doi.org/10.1161/01.ATV.14.1.8
doi: 10.1161/01.ATV.14.1.8
pubmed: 8274481
De Fabiani E, Mitro N, Anzulovich AC, Pinelli A, Galli G, Crestani M (2001) The negative effects of bile acids and tumor necrosis factor-alpha on the transcription of cholesterol 7alpha-hydroxylase gene (CYP7A1) converge to hepatic nuclear factor-4: a novel mechanism of feedback regulation of bile acid synthesis mediated by nuclear receptors. J Biol Chem 276(33):30708–30716. https://doi.org/10.1074/JBC.M103270200
doi: 10.1074/JBC.M103270200
pubmed: 11402042
Memon RA, Moser AH, Shigenaga JK, Grunfeld C, Feingold KR (2001) In vivo and in vitro regulation of sterol 27-hydroxylase in the liver during the acute phase response. potential role of hepatocyte nuclear factor-1. J Biol Chem 276(32):30118–30126. https://doi.org/10.1074/JBC.M102516200
Feingold KR, Krauss RM, Pang M, Doerrler W, Jensen P, Grunfeld C (1993) The hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B. J Clin Endocrinol Metab 76(6):1423–1427. https://doi.org/10.1210/JCEM.76.6.8501146
doi: 10.1210/JCEM.76.6.8501146
pubmed: 8501146
Ettinger WH, Miller LD, Albers JJ, Smith TK, Parks JS (1990) Lipopolysaccharide and tumor necrosis factor cause a fall in plasma concentration of lecithin: cholesterol acyltransferase in cynomolgus monkeys. J Lipid Res 31(6):1099–1107. https://doi.org/10.1016/S0022-2275(20)42750-6
doi: 10.1016/S0022-2275(20)42750-6
pubmed: 2373960
Hardardóttir I, Kunitake ST, Moser AH et al (1994) Endotoxin and cytokines increase hepatic messenger RNA levels and serum concentrations of apolipoprotein J (clusterin) in Syrian hamsters. J Clin Invest 94(3):1304–1309. https://doi.org/10.1172/JCI117449
doi: 10.1172/JCI117449
pubmed: 8083372
pmcid: 295216
Hoffman JS, Benditt EP (1983) Plasma clearance kinetics of the amyloid-related high density lipoprotein apoprotein, serum amyloid protein (apoSAA), in the mouse. Evidence for rapid apoSAA clearance. J Clin Invest 71(4):926–934. https://doi.org/10.1172/JCI110847
Feingold KR, Marshall M, Gulli R, Moser AH, Grunfeld C (1994) Effect of endotoxin and cytokines on lipoprotein lipase activity in mice. Arterioscler Thromb 14(11):1866–1872. https://doi.org/10.1161/01.ATV.14.11.1866
doi: 10.1161/01.ATV.14.11.1866
pubmed: 7947614
Feingold KR, Adi S, Staprans I et al (1990) Diet affects the mechanisms by which TNF stimulates hepatic triglyceride production. Am J Physiol 259(2 Pt 1). https://doi.org/10.1152/AJPENDO.1990.259.2.E177
Behl T, Kaur I, Sehgal A et al (2020) The lipid paradox as a metabolic checkpoint and its therapeutic significance in ameliorating the associated cardiovascular risks in rheumatoid arthritis patients. Int J Mol Sci 21(24):1–27. https://doi.org/10.3390/IJMS21249505
doi: 10.3390/IJMS21249505
Fragoulis GE, Soulaidopoulos S, Sfikakis PP, Dimitroulas T, Kitas GD (2021) Effect of biologics on cardiovascular inflammation: mechanistic insights and risk reduction. Published online. https://doi.org/10.2147/JIR.S282691
doi: 10.2147/JIR.S282691
Luo Y, Ren X, Weng S, Yan C, Mao Q, Peng D (2021) Improvements in high-density lipoprotein quantity and quality contribute to the cardiovascular benefits by anti-tumor necrosis factor therapies in rheumatoid arthritis: a systemic review and meta-analysis. Front Cardiovasc Med 8:765749. https://doi.org/10.3389/FCVM.2021.765749
doi: 10.3389/FCVM.2021.765749
pubmed: 34778416
pmcid: 8585789
Daïen CI, Duny Y, Barnetche T, Daurès JP, Combe B, Morel J (2012) Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis. Ann Rheum Dis 71(6):862–868. https://doi.org/10.1136/ANNRHEUMDIS-2011-201148
doi: 10.1136/ANNRHEUMDIS-2011-201148
pubmed: 22267329
Diabetes mellitus risk factors in rheumatoid arthritis: a systematic review and meta-analysis - PubMed. Accessed July 20, 2023. https://pubmed.ncbi.nlm.nih.gov/25535750/
Stavropoulos-Kalinoglou A, Metsios GS, Panoulas VF, Nightingale P, Koutedakis Y, Kitas GD (2012) Anti-tumour necrosis factor alpha therapy improves insulin sensitivity in normal-weight but not in obese patients with rheumatoid arthritis. Arthritis Res Ther 14(4):1–7. https://doi.org/10.1186/AR3900/FIGURES/1
doi: 10.1186/AR3900/FIGURES/1
Antohe JL, Bili A, Sartorius JA et al (2012) Diabetes mellitus risk in rheumatoid arthritis: reduced incidence with anti-tumor necrosis factor α therapy. Arthritis Care Res (Hoboken) 64(2):215–221. https://doi.org/10.1002/ACR.20657
doi: 10.1002/ACR.20657
pubmed: 21972198
Leporini C, Russo E, D`Angelo S et al (2018) Insulin-sensiting effects of tumor necrosis factor alpha inhibitors in rheumatoid arthritis: a systematic review and meta-analysis. Rev Recent Clin Trials 13(3):184–191. https://doi.org/10.2174/1574887113666180314100340
van den Oever IAM, Baniaamam M, Simsek S et al (2021) The effect of anti-TNF treatment on body composition and insulin resistance in patients with rheumatoid arthritis. Rheumatol Int 41(2):319–328. https://doi.org/10.1007/S00296-020-04666-6
doi: 10.1007/S00296-020-04666-6
pubmed: 32776224
Bartoloni E, Alunno A, Gerli R (2018) Hypertension as a cardiovascular risk factor in autoimmune rheumatic diseases. Nat Rev Cardiol 15(1):33–44. https://doi.org/10.1038/NRCARDIO.2017.118
doi: 10.1038/NRCARDIO.2017.118
pubmed: 28836617
Midtbo H, Gerdts E, Kvien TK et al (2015) Disease activity and left ventricular structure in patients with rheumatoid arthritis. Rheumatology (Oxford) 54(3):511–519. https://doi.org/10.1093/RHEUMATOLOGY/KEU368
doi: 10.1093/RHEUMATOLOGY/KEU368
pubmed: 25224414
Argnani L, Zanetti A, Carrara G et al (2021) Rheumatoid arthritis and cardiovascular risk: retrospective matched-cohort analysis based on the RECORD study of the Italian Society for Rheumatology. Front Med (Lausanne). 8. https://doi.org/10.3389/FMED.2021.745601
Urschel K, Cicha I (2015) TNF-α in the cardiovascular system: from physiology to therapy. Int J Interferon Cytokine Mediat Res 7:9–25. https://doi.org/10.2147/IJICMR.S64894
doi: 10.2147/IJICMR.S64894
Zhao Q, Hong D, Zhang Y, Sang Y, Yang Z, Zhang X (2015) Association between anti-TNF therapy for rheumatoid arthritis and hypertension: a meta-analysis of randomized controlled trials. Medicine 94(14). https://doi.org/10.1097/MD.0000000000000731
Solomon DH, Kremer J, Curtis JR et al (2010) Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity. Ann Rheum Dis 69(11):1920–1925. https://doi.org/10.1136/ARD.2009.122226
doi: 10.1136/ARD.2009.122226
pubmed: 20444756
Yang XZ, Chang Y, Wei W (2016) Endothelial dysfunction and inflammation: immunity in rheumatoid arthritis. Mediators Inflamm 2016. https://doi.org/10.1155/2016/6813016
Mantel Ä, Holmqvist M, Nyberg F et al (2015) Risk factors for the rapid increase in risk of acute coronary events in patients with new-onset rheumatoid arthritis: a nested case-control study. Arthritis Rheumatol 67(11):2845–2854. https://doi.org/10.1002/ART.39267
doi: 10.1002/ART.39267
pubmed: 26138387
Solomon DH, Reed GW, Kremer JM et al (2015) Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis and Rheumatology 67(6):1449–1455. https://doi.org/10.1002/ART.39098
doi: 10.1002/ART.39098
pubmed: 25776112
Ferraz-Amaro I, Corrales A, Quevedo-Abeledo JC et al (2021) Disease activity influences the reclassification of rheumatoid arthritis into very high cardiovascular risk. Arthritis Res Ther 23(1). https://doi.org/10.1186/S13075-021-02542-7
SCORE2 risk prediction algorithms (2021) new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J 42(25):2439–2454. https://doi.org/10.1093/EURHEARTJ/EHAB309
doi: 10.1093/EURHEARTJ/EHAB309
Erre GL, Cacciapaglia F, Sakellariou G et al (2022) C-reactive protein and 10-year cardiovascular risk in rheumatoid arthritis. Eur J Intern Med 104:49–54. https://doi.org/10.1016/J.EJIM.2022.07.001
doi: 10.1016/J.EJIM.2022.07.001
pubmed: 35821191
Cambridge G, Acharya J, Cooper JA, Edwards JC, Humphries SE (2013) Antibodies to citrullinated peptides and risk of coronary heart disease. Atherosclerosis 228(1):243–246. https://doi.org/10.1016/J.ATHEROSCLEROSIS.2013.02.009
doi: 10.1016/J.ATHEROSCLEROSIS.2013.02.009
pubmed: 23474125
López-Longo FJ, Oliver-Miñarro D, De La Torre I et al (2009) Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 61(4):419–424. https://doi.org/10.1002/ART.24390
doi: 10.1002/ART.24390
MacKey RH, Kuller LH, Deane KD et al (2015) Rheumatoid arthritis, anti-cyclic citrullinated peptide positivity, and cardiovascular disease risk in the women’s health initiative. Arthritis Rheumatol 67(9):2311–2322. https://doi.org/10.1002/ART.39198
doi: 10.1002/ART.39198
pubmed: 25988241
Turesson C, McClelland RL, Christianson TJH, Matteson EL (2007) Severe extra-articular disease manifestations are associated with an increased risk of first ever cardiovascular events in patients with rheumatoid arthritis. Ann Rheum Dis 66(1):70–75. https://doi.org/10.1136/ARD.2006.052506
doi: 10.1136/ARD.2006.052506
pubmed: 16877533
Mattey DL, Thomson W, Ollier WER et al (2007) Association of DRB1 shared epitope genotypes with early mortality in rheumatoid arthritis: results of eighteen years of followup from the early rheumatoid arthritis study. Arthritis Rheum 56(5):1408–1416. https://doi.org/10.1002/ART.22527
doi: 10.1002/ART.22527
pubmed: 17469097
Farragher TM, Goodson NJ, Naseem H et al (2008) Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis. Arthritis Rheum 58(2):359–369. https://doi.org/10.1002/ART.23149
doi: 10.1002/ART.23149
pubmed: 18240242
pmcid: 3001034
Sokka T, Häkkinen A, Kautiainen H et al (2008) Physical inactivity in patients with rheumatoid arthritis: data from twenty-one countries in a cross-sectional, international study. Arthritis Care Res (Hoboken) 59(1):42–50. https://doi.org/10.1002/ART.23255
doi: 10.1002/ART.23255
Doumen M, Pazmino S, Bertrand D, Westhovens R, Verschueren P (2023) Glucocorticoids in rheumatoid arthritis: balancing benefits and harm by leveraging the therapeutic window of opportunity. Joint Bone Spine 90(3):105491. https://doi.org/10.1016/J.JBSPIN.2022.105491
doi: 10.1016/J.JBSPIN.2022.105491
pubmed: 36410680
Aviña-zubieta JA, Abrahamowicz M, De vera MA et al (2013) Immediate and past cumulative effects of oral glucocorticoids on the risk of acute myocardial infarction in rheumatoid arthritis: a population-based study. Rheumatology (Oxford). 52(1):68–75. https://doi.org/10.1093/RHEUMATOLOGY/KES353
Del Rincón I, Battafarano DF, Restrepo JF, Erikson JM, Escalante A (2014) Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthritis and Rheumatology 66(2):264–272. https://doi.org/10.1002/ART.38210
doi: 10.1002/ART.38210
pubmed: 24504798
Ghosh R, Alajbegovic A, Gomes AV (2015) NSAIDs and cardiovascular diseases: role of reactive oxygen species. Oxid Med Cell Longev 2015. https://doi.org/10.1155/2015/536962
González-Gay MA, González-Juanatey C (2017) Inflammation: NSAIDs and cardiovascular risk in arthritis. Nat Rev Cardiol 14(2):69–70. https://doi.org/10.1038/NRCARDIO.2016.208
doi: 10.1038/NRCARDIO.2016.208
pubmed: 28054573
Jacobsson LTH, Turesson C, Nilsson JÅ et al (2007) Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 66(5):670–675. https://doi.org/10.1136/ARD.2006.062497
doi: 10.1136/ARD.2006.062497
pubmed: 17158824
Ljung L, Askling J, Rantapää-Dahlqvist S et al (2014) The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study. Arthritis Res Ther 16(3). https://doi.org/10.1186/AR4584
Solomon DH, Curtis JR, Saag KG et al (2013) Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDs. Am J Med 126(8):730.e9-730.e17. https://doi.org/10.1016/J.AMJMED.2013.02.016
doi: 10.1016/J.AMJMED.2013.02.016
pubmed: 23885678
Greenberg JD, Kremer JM, Curtis JR et al (2011) Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 70(4):576–582. https://doi.org/10.1136/ARD.2010.129916
doi: 10.1136/ARD.2010.129916
pubmed: 21109516
Ozen G, Pedro S, Michaud K (2021) The risk of cardiovascular events associated with disease-modifying antirheumatic drugs in rheumatoid arthritis. J Rheumatol 48(5):648–655. https://doi.org/10.3899/JRHEUM.200265
doi: 10.3899/JRHEUM.200265
pubmed: 32801134
Dixon WG, Watson KD, Lunt M et al (2007) Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 56(9):2905–2912. https://doi.org/10.1002/ART.22809
doi: 10.1002/ART.22809
pubmed: 17763428
pmcid: 2435427
Low ASL, Lunt M, Mercer LK et al (2016) Association between ischemic stroke and tumor necrosis factor inhibitor therapy in patients with rheumatoid arthritis. Arthritis Rheumatol 68(6):1337–1345. https://doi.org/10.1002/ART.39582
doi: 10.1002/ART.39582
pubmed: 26749043
pmcid: 4982051
Singh S, Fumery M, Singh AG et al (2020) Comparative risk of cardiovascular events with biologic and synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 72(4):561–576. https://doi.org/10.1002/ACR.23875
doi: 10.1002/ACR.23875
pubmed: 30875456
Giles JT, Sattar N, Gabriel S et al (2020) Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial. Arthritis Rheumatol 72(1):31–40. https://doi.org/10.1002/ART.41095
doi: 10.1002/ART.41095
pubmed: 31469238
Kim SC, Solomon DH, Rogers JR et al (2017) Cardiovascular safety of tocilizumab versus tumor necrosis factor inhibitors in patients with rheumatoid arthritis: a multi-database cohort study. Arthritis Rheumatol 69(6):1154–1164. https://doi.org/10.1002/ART.40084
doi: 10.1002/ART.40084
pubmed: 28245350
pmcid: 5573926
Zhang J, Xie F, Yun H et al (2016) Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis. Ann Rheum Dis 75(10):1813–1818. https://doi.org/10.1136/ANNRHEUMDIS-2015-207870
doi: 10.1136/ANNRHEUMDIS-2015-207870
pubmed: 26792814
Jin Y, Kang EH, Brill G, Desai RJ, Kim SC (2018) Cardiovascular (CV) risk after initiation of abatacept versus TNF inhibitors in rheumatoid arthritis patients with and without baseline CV disease. J Rheumatol 45(9):1240–1248. https://doi.org/10.3899/JRHEUM.170926
doi: 10.3899/JRHEUM.170926
pubmed: 29764964
Queiroz MJ de, Castro CT de, Albuquerque FC et al (2022) Safety of biological therapy in patients with rheumatoid arthritis in administrative health databases: a systematic review and meta-analysis. Front Pharmacol 13. https://doi.org/10.3389/FPHAR.2022.928471
Khosrow-Khavar F, Kim SC, Lee H, Lee SB, Desai RJ (2022) Tofacitinib and risk of cardiovascular outcomes: results from the Safety of Tofacitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study. Ann Rheum Dis 81(6). https://doi.org/10.1136/ANNRHEUMDIS-2021-221915
Salinas CA, Louder A, Polinski J et al (2023) Evaluation of VTE, MACE, and serious infections among patients with RA treated with baricitinib compared to TNFi: a multi-database study of patients in routine care using disease registries and claims databases. Rheumatol Ther 10(1):201–223. https://doi.org/10.1007/S40744-022-00505-1
doi: 10.1007/S40744-022-00505-1
pubmed: 36371760
Plein S, Erhayiem B, Fent G et al (2020) Cardiovascular effects of biological versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-naïve, early rheumatoid arthritis. Ann Rheum Dis 79(11):1414–1422. https://doi.org/10.1136/ANNRHEUMDIS-2020-217653
doi: 10.1136/ANNRHEUMDIS-2020-217653
pubmed: 32859608
Solomon DH, Giles JT, Liao KP et al (2023) Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritis. Ann Rheum Dis 82(3):324–330. https://doi.org/10.1136/ARD-2022-223302
doi: 10.1136/ARD-2022-223302
pubmed: 36450449
van Sijl AM, Peters MJ, Knol DK et al (2011) Carotid intima media thickness in rheumatoid arthritis as compared to control subjects: a meta-analysis. Semin Arthritis Rheum 40(5):389–397. https://doi.org/10.1016/J.SEMARTHRIT.2010.06.006
doi: 10.1016/J.SEMARTHRIT.2010.06.006
pubmed: 20889191
Vassilopoulos D, Gravos A, Vlachopoulos C et al (2015) Adalimumab decreases aortic stiffness independently of its effect in disease activity in patients with rheumatoid arthritis. Clin Rheumatol 34(2):359–364. https://doi.org/10.1007/S10067-014-2718-8/METRICS
doi: 10.1007/S10067-014-2718-8/METRICS
pubmed: 24928345
Abdulmajid B, Blanken AB, van Geel EH, Daams JG, Nurmohamed MT (2023) Effect of TNF inhibitors on arterial stiffness and intima media thickness in rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol 42(4). https://doi.org/10.1007/S10067-023-06505-Y
McDonagh TA, Metra M, Adamo M et al (2022) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Rev Esp Cardiol (Engl Ed) 75(6):523. https://doi.org/10.1016/J.REC.2022.05.005
doi: 10.1016/J.REC.2022.05.005
pubmed: 35636830
Roger VL (2013) Epidemiology of heart failure. Circ Res 113(6):646–659. https://doi.org/10.1161/CIRCRESAHA.113.300268
doi: 10.1161/CIRCRESAHA.113.300268
pubmed: 23989710
pmcid: 3806290
Federmann M, Hess OM (1994) Differentiation between systolic and diastolic dysfunction. Eur Heart J 15(suppl_D):2–6. https://doi.org/10.1093/EURHEARTJ/15.SUPPL_D.2
Schau T, Gottwald M, Arbach O et al (2015) Increased prevalence of diastolic heart failure in patients with rheumatoid arthritis correlates with active disease, but not with treatment type. J Rheumatol 42(11):2029–2037. https://doi.org/10.3899/JRHEUM.141647
doi: 10.3899/JRHEUM.141647
pubmed: 26373561
Kotyla PJ (2018) Bimodal function of anti-TNF treatment: shall we be concerned about anti-TNF treatment in patients with rheumatoid arthritis and heart failure?. Int J Mol Sci 19(6):1739. https://doi.org/10.3390/IJMS19061739
Thielmann M, Dörge H, Martin C et al (2002) Myocardial dysfunction with coronary microembolization: signal transduction through a sequence of nitric oxide, tumor necrosis factor-alpha, and sphingosine. Circ Res 90(7):807–813. https://doi.org/10.1161/01.RES.0000014451.75415.36
doi: 10.1161/01.RES.0000014451.75415.36
pubmed: 11964374
Kleinbongard P, Schulz R, Heusch G (2011) TNFα in myocardial ischemia/reperfusion, remodeling and heart failure. Heart Fail Rev 16(1):49–69. https://doi.org/10.1007/S10741-010-9180-8
doi: 10.1007/S10741-010-9180-8
pubmed: 20571888
Lee CT, Chen LW, Chien MY (2017) Effects of exercise training on anabolic and catabolic markers in patients with chronic heart failure: a systematic review. Heart Fail Rev 22(6):723–730. https://doi.org/10.1007/S10741-017-9639-Y
doi: 10.1007/S10741-017-9639-Y
pubmed: 28695463
Takeuchi T, Miyasaka N, Inui T et al (2017) High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the RISING study. Arthritis Res Ther 19(1). https://doi.org/10.1186/S13075-017-1401-2
Miettinen KH, Lassus J, Harjola VP et al (2008) Prognostic role of pro- and anti-inflammatory cytokines and their polymorphisms in acute decompensated heart failure. Eur J Heart Fail 10(4):396–403. https://doi.org/10.1016/J.EJHEART.2008.02.008
doi: 10.1016/J.EJHEART.2008.02.008
pubmed: 18353715
Defer N, Azroyan A, Pecker F, Pavoine C (2007) TNFR1 and TNFR2 signaling interplay in cardiac myocytes. J Biol Chem 282(49):35564–35573. https://doi.org/10.1074/JBC.M704003200
doi: 10.1074/JBC.M704003200
pubmed: 17913704
Hussain A, Tarahomi T, Singh L, Bollampally M, Heydari-Kamjani M, Kesselman MM (2021) Cardiovascular risk associated with TNF alpha inhibitor use in patients with rheumatoid arthritis. Cureus 13(9). https://doi.org/10.7759/CUREUS.17938
Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT (2003) Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure. Circulation 107(25):3133–3140. https://doi.org/10.1161/01.CIR.0000077913.60364.D2
doi: 10.1161/01.CIR.0000077913.60364.D2
pubmed: 12796126
Mann DL, McMurray JJV, Packer M et al (2004) Targeted anticytokine therapy in patients with chronic heart failure. Circulation 109(13):1594–1602. https://doi.org/10.1161/01.CIR.0000124490.27666.B2
doi: 10.1161/01.CIR.0000124490.27666.B2
pubmed: 15023878
Listing J, Strangfeld A, Kekow J et al (2008) Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Arthritis Rheum 58(3):667–677. https://doi.org/10.1002/ART.23281
doi: 10.1002/ART.23281
pubmed: 18311816
Vizzardi E, Cavazzana I, Franceschini F et al (2016) Left ventricular function in rheumatoid arthritis during anti-TNF-α treatment: a speckle tracking prospective echocardiographic study. Monaldi Arch Chest Dis 84(1–2). https://doi.org/10.4081/MONALDI.2015.716
Chen HK, Shao SC, Weng MY et al (2021) Risk of heart failure in rheumatoid arthritis patients treated with tumor necrosis factor-α inhibitors. Clin Pharmacol Ther 110(6):1595–1603. https://doi.org/10.1002/CPT.2415
doi: 10.1002/CPT.2415
pubmed: 34496051
Generali E, Carrara G, Kallikourdis M et al (2019) Risk of hospitalization for heart failure in rheumatoid arthritis patients treated with etanercept and abatacept. Rheumatol Int 39(2):239–243. https://doi.org/10.1007/S00296-018-4196-9
doi: 10.1007/S00296-018-4196-9
pubmed: 30413926
Chung WS, Peng CL, Lin CL et al (2014) Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study. Ann Rheum Dis 73(10):1774–1780. https://doi.org/10.1136/ANNRHEUMDIS-2013-203380
doi: 10.1136/ANNRHEUMDIS-2013-203380
pubmed: 23926057
Ketfi C, Boutigny A, Mohamedi N et al (2021) Risk of venous thromboembolism in rheumatoid arthritis. Joint Bone Spine 88(3). https://doi.org/10.1016/J.JBSPIN.2020.105122
Głuszek J, Wierzowiecka M, Niklas K, Niklas A (2020) The importance of homocysteine in the development of cardiovascular complications in patients with rheumatoid arthritis. Reumatologia 58(5):282–288. https://doi.org/10.5114/REUM.2020.99732
doi: 10.5114/REUM.2020.99732
pubmed: 33227081
pmcid: 7667944
Gladd DA, Olech E (2009) Antiphospholipid antibodies in rheumatoid arthritis: identifying the dominoes. Curr Rheumatol Rep 11(1):43–51. https://doi.org/10.1007/S11926-009-0007-3
doi: 10.1007/S11926-009-0007-3
pubmed: 19171111
Kolarz B, Majdan M, Darmochwał-Kolarz DA, Dryglewska M (2014) Antiphospholipid antibodies during 6-month treatment with infliximab: a preliminary report. Med Sci Monit 20:1227–1231. https://doi.org/10.12659/MSM.890270
doi: 10.12659/MSM.890270
pubmed: 25027437
pmcid: 4109570
Ingegnoli F, Fantini F, Favalli EG et al (2008) Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade. J Autoimmun 31(2):175–179. https://doi.org/10.1016/J.JAUT.2008.07.002
doi: 10.1016/J.JAUT.2008.07.002
pubmed: 18707846
Davies R, Galloway JB, Watson KD et al (2011) Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 70(10):1831–1834. https://doi.org/10.1136/ARD.2011.153536
doi: 10.1136/ARD.2011.153536
pubmed: 21784722
Merkel PA, Jayne D, Yue H et al (2020) OP0012 TNF inhibitors are associated with a reduced risk of venous thromboembolism compared to CSDMARDS in RA patients. Ann Rheum Dis 79(Suppl 1):8–9. https://doi.org/10.1136/ANNRHEUMDIS-2020-EULAR.1505
doi: 10.1136/ANNRHEUMDIS-2020-EULAR.1505
Desai RJ, Pawar A, Weinblatt ME, Kim SC (2019) Comparative risk of venous thromboembolism in rheumatoid arthritis patients receiving tofacitinib versus those receiving tumor necrosis factor inhibitors: an observational cohort study. Arthritis Rheumatol 71(6):892–900. https://doi.org/10.1002/ART.40798
doi: 10.1002/ART.40798
pubmed: 30552833
Hoisnard L, Pina Vegas L, Dray-Spira R, Weill A, Zureik M, Sbidian E (2023) Risk of major adverse cardiovascular and venous thromboembolism events in patients with rheumatoid arthritis exposed to JAK inhibitors versus adalimumab: a nationwide cohort study. Ann Rheum Dis 82(2):182–188. https://doi.org/10.1136/ARD-2022-222824
doi: 10.1136/ARD-2022-222824
pubmed: 36198438
Sepriano A, Kerschbaumer A, Bergstra SA et al (2023) Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 82(1):107–118. https://doi.org/10.1136/ARD-2022-223357
doi: 10.1136/ARD-2022-223357
pubmed: 36376026
Fleischmann R, Mysler E, Bessette L et al (2022) Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study. RMD Open 8(1). https://doi.org/10.1136/RMDOPEN-2021-002012
Taylor PC, Keystone EC, van der Heijde D et al (2017) Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med 376(7):652–662. https://doi.org/10.1056/NEJMOA1608345
doi: 10.1056/NEJMOA1608345
pubmed: 28199814
Combe B, Kivitz A, Tanaka Y et al (2021) Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. Ann Rheum Dis 80(7):848–858. https://doi.org/10.1136/ANNRHEUMDIS-2020-219214
doi: 10.1136/ANNRHEUMDIS-2020-219214
pubmed: 33504485
Meissner Y, Schäfer M, Albrecht K et al (2023) Original research: risk of major adverse cardiovascular events in patients with rheumatoid arthritis treated with conventional synthetic, biologic and targeted synthetic disease-modifying antirheumatic drugs: observational data from the German RABBIT register. RMD Open 9(4):e003489. https://doi.org/10.1136/RMDOPEN-2023-003489
doi: 10.1136/RMDOPEN-2023-003489
pubmed: 37880180
pmcid: 10603345
Heidenreich PA, Bozkurt B, Aguilar D et al (2022) 2022 AHA/ACC/HFSA Guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation 145(18):E895–E1032. https://doi.org/10.1161/CIR.0000000000001063
doi: 10.1161/CIR.0000000000001063
pubmed: 35363499